中關村(000931.SZ):化學仿製藥蒙脱石散的藥品註冊申請獲受理
格隆匯4月20日丨中關村(000931.SZ)公佈,近日,公司全資子公司北京中關村四環醫藥開發有限責任公司之控股子公司多多藥業有限公司(以下簡稱:多多藥業)收到國家藥品監督管理局籤發的化學仿製藥蒙脱石散藥品註冊申請的《受理通知書》。
多多藥業的蒙脱石散仿製藥申請獲得國家藥監局的受理,標誌着該品種研製工作進入審查階段,公司將積極推進後續相關工作,如獲得生產批件,將增加消化類產品的市場競爭力,對公司的經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.